- Home
- SNTG vs QLGN Comparison
SNTG vs QLGN Comparison
Compare SNTG & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTG
- QLGN
- Stock Information
- Founded
- SNTG 2009
- QLGN 1996
- Country
- SNTG China
- QLGN United States
- Employees
- SNTG N/A
- QLGN N/A
- Industry
- SNTG Finance: Consumer Services
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- SNTG Finance
- QLGN Health Care
- Exchange
- SNTG Nasdaq
- QLGN Nasdaq
- Market Cap
- SNTG 4.8M
- QLGN 4.7M
- IPO Year
- SNTG 2021
- QLGN N/A
- Fundamental
- Price
- SNTG $1.94
- QLGN $2.80
- Analyst Decision
- SNTG
- QLGN
- Analyst Count
- SNTG 0
- QLGN 0
- Target Price
- SNTG N/A
- QLGN N/A
- AVG Volume (30 Days)
- SNTG 7.3K
- QLGN 2.5M
- Earning Date
- SNTG 08-05-2025
- QLGN 07-21-2025
- Dividend Yield
- SNTG N/A
- QLGN N/A
- EPS Growth
- SNTG N/A
- QLGN N/A
- EPS
- SNTG N/A
- QLGN N/A
- Revenue
- SNTG $107,507.00
- QLGN N/A
- Revenue This Year
- SNTG N/A
- QLGN N/A
- Revenue Next Year
- SNTG N/A
- QLGN N/A
- P/E Ratio
- SNTG N/A
- QLGN N/A
- Revenue Growth
- SNTG N/A
- QLGN N/A
- 52 Week Low
- SNTG $1.43
- QLGN $2.60
- 52 Week High
- SNTG $3.52
- QLGN $13.43
- Technical
- Relative Strength Index (RSI)
- SNTG 53.91
- QLGN 35.34
- Support Level
- SNTG $1.93
- QLGN $2.77
- Resistance Level
- SNTG $1.96
- QLGN $3.29
- Average True Range (ATR)
- SNTG 0.08
- QLGN 0.54
- MACD
- SNTG -0.01
- QLGN -0.06
- Stochastic Oscillator
- SNTG 30.36
- QLGN 5.38
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.